Tuesday, 07 Apr 2020

You are here

Scleroderma Digital Ulcers Fail to Respond to Endothelin Antagonist

Khanna and coworkers have published the results of the DUAL-1 and DUAL-2 clinical trials (sponsored by Actelion Pharmaceuticals) testing the efficacy macitentan in reducing the number of new digital ulcers in patients with systemic sclerosis. The results appear in the May 10th issue of JAMA.

Digital ulcers occur in 35 percent to 68 percent of patients with systemic sclerosis, and are associated with pain, disfigurement, poor quality of life, and disability. Macitentan, an endothelian receptor antagonist, is currently approved for long-term treatment of pulmonary arterial hypertension.

The DUAL-1, DUAL-2 clinical trials treated patients with systemic sclerosis with active digital ulcers and were randomly assigned to receive oral doses of 3 mg of macitentan, 10 mg of macitentan, or placebo once daily and stratified according to number of digital ulcers at baseline. Overall 554 patients were enrolled and 442 completed the trials. Macitentan did not reduce the cumulative number of new digital ulcers over 16 weeks compared with placebo. However, one of the problems of this study was that patients had few new digital ulcers (roughly 1 new ulcer per patient) and their overall digital ulcer condition remained stable over 16 weeks.

Adverse events more frequently seen with macitentan included headache, peripheral edema, skin ulcer, anemia, upper respiratory tract infection, diarrhea, and nasopharyngitis.

The results do not support this agen in the treatment of digital ulcers.  Moreover, these results are disappointing given the few effective optoins that exist for such patients. The recent SEDUCE trial failed to prove the benefit of sildenafil in patients with chronic digital ulcerations. (Citation source: http://t.co/SpBWnKeq7L)

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

In Lupus, Keep BP Below 130/80

Blood pressure should be maintained at a level below 130/80 mm Hg in all patients with lupus to lessen their likelihood of atherosclerotic vascular events, Canadian researchers asserted.

In Vasculitis, Beware of Infection

Risks of infection were strikingly high among patients with antineutrophil cytoplasmic antibody-associated (ANCA) vasculitis, which may relate to both the disease and its treatment, Scottish researchers found.

Malignancies with Giant Cell Arteritis

The Journal of Rheumatology reports the findings of a Swedish population-based cohort study of biopsy-proven giant cell arteritis (GCA) patients showing that the overall risk for cancer was not increased; yet there appears to be an increased risk for leukemia and a decreased risk for breast and upper gastrointestinal tract cancers.   

Hospitalized GPA - Higher morbidity, Mortality and Cost

Rheumatology reports on a study of patients with granulomatosis with polyangiitis (GPA) showing worse outcomes and higher costs when hospitalized with GPA.

GPA patients were identified from the Nationwide Inpatient Sample (NIS) and were compared to those without GPA with regard to demographics, procedures, length of stay, mortality, morbidity and total hospitalization charges (between 2005–2014).

Don't Blame the Weather in Sjogren's

Seasonal variations in symptoms -- commonly reported by patients with rheumatic diseases -- were not observed in a large cohort of patients with primary Sjogren's syndrome, French investigators found.